The efficacy and safety of rituximab in treating childhood nephrotic syndrome: An Italian perspective

Dario Maratea, Monica Bettio, Maria Grazia Corti, Giovanni Montini, Francesca Venturini

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Nephrotic syndrome is a disorder characterized by proteinuria, hypoalbuminemia and dyslipidemia. Low-dose alternate-day steroid regimen is the standard of care. In case of relapse or significant adverse events, steroid-sparing agents may be used. This analysis was aimed at assessing the efficacy and safety of rituximab for the treatment of children with nephrotic syndrome. Results: Four studies were included in the final meta-analysis. The end-point of our analysis was the percentage of patients in remission at 6 months. Pooled data from the four studies favours the use of rituximab (RR 5.25, 95 % CI: 3.05-9.06; p <0.0001). As regards the safety data, rituximab has a limited number of adverse effects, the most common of which occur during the infusions. Conclusions: In Italy, the off-label use of drugs is regulated by Law 648/96. In our opinion, there are three scientific requirements to merit a conditional national reimbursement for rituximab in nephrotic syndrome: 1. favourable clinical efficacy and safety data; 2. no available alternatives; 3. outcome data collecting by AIFA through prescribers. In conclusion, our results report a significant incremental benefit of adding rituximab to corticosteroid and/or calcineurin inhibitors for the treatment of nephrotic syndrome.

Original languageEnglish
Article number63
JournalItalian Journal of Pediatrics
Volume42
Issue number1
DOIs
Publication statusPublished - Jul 12 2016

Fingerprint

Nephrotic Syndrome
Safety
Steroids
Off-Label Use
Hypoalbuminemia
Standard of Care
Dyslipidemias
Proteinuria
Italy
Meta-Analysis
Adrenal Cortex Hormones
Rituximab
Recurrence
Therapeutics
Pharmaceutical Preparations

Keywords

  • 648/96 law
  • Nephrotic syndrome
  • Off label
  • Reimbursement
  • Rituximab

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

The efficacy and safety of rituximab in treating childhood nephrotic syndrome : An Italian perspective. / Maratea, Dario; Bettio, Monica; Corti, Maria Grazia; Montini, Giovanni; Venturini, Francesca.

In: Italian Journal of Pediatrics, Vol. 42, No. 1, 63, 12.07.2016.

Research output: Contribution to journalArticle

Maratea, Dario ; Bettio, Monica ; Corti, Maria Grazia ; Montini, Giovanni ; Venturini, Francesca. / The efficacy and safety of rituximab in treating childhood nephrotic syndrome : An Italian perspective. In: Italian Journal of Pediatrics. 2016 ; Vol. 42, No. 1.
@article{fe2bf585b5a8443ea615bf985bf752e1,
title = "The efficacy and safety of rituximab in treating childhood nephrotic syndrome: An Italian perspective",
abstract = "Background: Nephrotic syndrome is a disorder characterized by proteinuria, hypoalbuminemia and dyslipidemia. Low-dose alternate-day steroid regimen is the standard of care. In case of relapse or significant adverse events, steroid-sparing agents may be used. This analysis was aimed at assessing the efficacy and safety of rituximab for the treatment of children with nephrotic syndrome. Results: Four studies were included in the final meta-analysis. The end-point of our analysis was the percentage of patients in remission at 6 months. Pooled data from the four studies favours the use of rituximab (RR 5.25, 95 {\%} CI: 3.05-9.06; p <0.0001). As regards the safety data, rituximab has a limited number of adverse effects, the most common of which occur during the infusions. Conclusions: In Italy, the off-label use of drugs is regulated by Law 648/96. In our opinion, there are three scientific requirements to merit a conditional national reimbursement for rituximab in nephrotic syndrome: 1. favourable clinical efficacy and safety data; 2. no available alternatives; 3. outcome data collecting by AIFA through prescribers. In conclusion, our results report a significant incremental benefit of adding rituximab to corticosteroid and/or calcineurin inhibitors for the treatment of nephrotic syndrome.",
keywords = "648/96 law, Nephrotic syndrome, Off label, Reimbursement, Rituximab",
author = "Dario Maratea and Monica Bettio and Corti, {Maria Grazia} and Giovanni Montini and Francesca Venturini",
year = "2016",
month = "7",
day = "12",
doi = "10.1186/s13052-016-0271-6",
language = "English",
volume = "42",
journal = "Italian Journal of Pediatrics",
issn = "1720-8424",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - The efficacy and safety of rituximab in treating childhood nephrotic syndrome

T2 - An Italian perspective

AU - Maratea, Dario

AU - Bettio, Monica

AU - Corti, Maria Grazia

AU - Montini, Giovanni

AU - Venturini, Francesca

PY - 2016/7/12

Y1 - 2016/7/12

N2 - Background: Nephrotic syndrome is a disorder characterized by proteinuria, hypoalbuminemia and dyslipidemia. Low-dose alternate-day steroid regimen is the standard of care. In case of relapse or significant adverse events, steroid-sparing agents may be used. This analysis was aimed at assessing the efficacy and safety of rituximab for the treatment of children with nephrotic syndrome. Results: Four studies were included in the final meta-analysis. The end-point of our analysis was the percentage of patients in remission at 6 months. Pooled data from the four studies favours the use of rituximab (RR 5.25, 95 % CI: 3.05-9.06; p <0.0001). As regards the safety data, rituximab has a limited number of adverse effects, the most common of which occur during the infusions. Conclusions: In Italy, the off-label use of drugs is regulated by Law 648/96. In our opinion, there are three scientific requirements to merit a conditional national reimbursement for rituximab in nephrotic syndrome: 1. favourable clinical efficacy and safety data; 2. no available alternatives; 3. outcome data collecting by AIFA through prescribers. In conclusion, our results report a significant incremental benefit of adding rituximab to corticosteroid and/or calcineurin inhibitors for the treatment of nephrotic syndrome.

AB - Background: Nephrotic syndrome is a disorder characterized by proteinuria, hypoalbuminemia and dyslipidemia. Low-dose alternate-day steroid regimen is the standard of care. In case of relapse or significant adverse events, steroid-sparing agents may be used. This analysis was aimed at assessing the efficacy and safety of rituximab for the treatment of children with nephrotic syndrome. Results: Four studies were included in the final meta-analysis. The end-point of our analysis was the percentage of patients in remission at 6 months. Pooled data from the four studies favours the use of rituximab (RR 5.25, 95 % CI: 3.05-9.06; p <0.0001). As regards the safety data, rituximab has a limited number of adverse effects, the most common of which occur during the infusions. Conclusions: In Italy, the off-label use of drugs is regulated by Law 648/96. In our opinion, there are three scientific requirements to merit a conditional national reimbursement for rituximab in nephrotic syndrome: 1. favourable clinical efficacy and safety data; 2. no available alternatives; 3. outcome data collecting by AIFA through prescribers. In conclusion, our results report a significant incremental benefit of adding rituximab to corticosteroid and/or calcineurin inhibitors for the treatment of nephrotic syndrome.

KW - 648/96 law

KW - Nephrotic syndrome

KW - Off label

KW - Reimbursement

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84978720935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978720935&partnerID=8YFLogxK

U2 - 10.1186/s13052-016-0271-6

DO - 10.1186/s13052-016-0271-6

M3 - Article

AN - SCOPUS:84978720935

VL - 42

JO - Italian Journal of Pediatrics

JF - Italian Journal of Pediatrics

SN - 1720-8424

IS - 1

M1 - 63

ER -